Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zhuang-Zhong Chen"'
Autor:
Rui-Lian Chen, Jing-Xu Zhou, Yang Cao, Ling-Ling Sun, Shan Su, Xiao-Jie Deng, Jie-Tao Lin, Zhi-Wei Xiao, Zhuang-Zhong Chen, Si-Yu Wang, Li-Zhu Lin
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
BackgroundLimited treatment strategies are available for squamous-cell lung cancer (SQLC) patients. Few studies have addressed whether immune-related genes (IRGs) or the tumor immune microenvironment can predict the prognosis for SQLC patients. Our s
Externí odkaz:
https://doaj.org/article/4199d2e347e04bdebbe5b92ab7e61560
Publikováno v:
Chinese Journal of Integrative Medicine. 26:256-262
To evaluate the effect of Chinese herbal medicine formula, modified Liujunzi Decoction (六君子汤, MLJZT), for anorexia, utilized as adjunct therapy during chemotherapy treatment for patients with advanced non-small cell lung cancer (NSCLC). The s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d45e4a18c59cb4c93fb583670dc4859
https://doi.org/10.1007/s11655-020-3185-5
https://doi.org/10.1007/s11655-020-3185-5
Autor:
Xiang-Jun, Qi, Xin-Rong, Chen, Jia-Hao, Mo, Pei-Xin, Li, Meng-Yi, Cai, Wan-Ning, Lan, Han-Rui, Chen, Zhuang-Zhong, Chen, Guo-Ming, Chen, Li-Zhu, Lin
Publikováno v:
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 46(15)
The tumor prescriptions contained in Dictionary of Tumor Formulas, Compendium of Good Tumor Formulas, Chinese Pharmacopoeia, Ministry of Health Drug Standards for Chinese Medicine Formulas and National Compilation of Standards for Proprietary Chinese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::628c05e792d08241c27340ffb24f3e10
https://pubmed.ncbi.nlm.nih.gov/34472279
https://pubmed.ncbi.nlm.nih.gov/34472279
Autor:
Jue Zhang, Lingling Sun, Lizhu Lin, Thazin Nwe Aung, Xiaomin Liu, Zhuang-Zhong Chen, Jian Cui, David L. Adelson, Zhipeng Qu, Jing Wang
Publikováno v:
Cytometry
High incidence and mortality rates for non‐small‐cell lung cancer (NSCLC) lead to low survival rates. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) are commonly first prescribed for NSCLC patients with EGFR mutations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab48cb8a564c0d7e148e707ce75157b
https://doi.org/10.1002/cyto.a.23869
https://doi.org/10.1002/cyto.a.23869
Autor:
Sheng Huang, Zhuang-Zhong Chen, Jia‐Hui Liu, Xiao-Zhong Liao, Hanrui Chen, Lizhu Lin, Ling Yu, Ying Gao, Lingling Sun, Jia‐Xing Zhang
Publikováno v:
Phytotherapy Research
Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ec6b45c70067a57fd4d8c9367beead
http://europepmc.org/articles/PMC6772065
http://europepmc.org/articles/PMC6772065
Autor:
Yang Cao, Si Yu Wang, Zhi Wei Xiao, Li Zhu Lin, Xiao Jie Deng, Zhuang Zhong Chen, Jing Xu Zhou, Jie Tao Lin, Shan Su, Rui Lian Chen, Ling Ling Sun
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Background Limited treatment strategies are available for squamous-cell lung cancer (SQLC) patients. Few studies have addressed whether immune-related genes (IRGs) or the tumor immune microenvironment can predict the prognosis for SQLC patients. Our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1da4854452c4b9c85bb9e0de88b9da92
http://europepmc.org/articles/PMC7533590
http://europepmc.org/articles/PMC7533590
Autor:
Lizhu Lin, Lingling Sun, Ling Yu, Jia-Hui Liu, Hanrui Chen, Xiao-Zhong Liao, Ying Gao, Zhuang-Zhong Chen, Wen-Hui Chen
Publikováno v:
Phytotherapy Research
Cisplatin (DDP) is one of the first-line chemotherapeutic agents for non-small cell lung cancer (NSCLC). However, repeated use of cisplatin in clinical practice often induces chemoresistance. The aims of this study were to investigate whether rosmari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a059694af41702b20ac0f921ae48ef
https://pubmed.ncbi.nlm.nih.gov/31985119
https://pubmed.ncbi.nlm.nih.gov/31985119
Publikováno v:
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 35(2)
To study the predicting effect of proly 4-hydroxylase beta polypeptide (P4HB) in treating non-small cell lung cancer (NSCLC) patients by Yiqi Chutan Recipe (YCR).Totally 46 stage III and IV NSCLC patients were treated by YCR for 4 therapeutic courses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b20c355ffa4738223b00bff506f76f80
https://pubmed.ncbi.nlm.nih.gov/25881463
https://pubmed.ncbi.nlm.nih.gov/25881463